{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T16:30:35Z","timestamp":1784565035787,"version":"3.55.0"},"reference-count":13,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T00:00:00Z","timestamp":1609977600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofsubstanceabusetreatment.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Substance Abuse Treatment"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.jsat.2021.108276","type":"journal-article","created":{"date-parts":[[2021,1,8]],"date-time":"2021-01-08T18:49:14Z","timestamp":1610131754000},"page":"108276","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":113,"special_numbering":"C","title":["Take-home dosing experiences among persons receiving methadone maintenance treatment during COVID-19"],"prefix":"10.1016","volume":"123","author":[{"given":"Mary C.","family":"Figgatt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zach","family":"Salazar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Day","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Vincent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nabarun","family":"Dasgupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jsat.2021.108276_bb0005","article-title":"Continuing increased access to buprenorphine in the United States via telemedicine after COVID-19","author":"Davis","year":"2020","journal-title":"International Journal of Drug Policy"},{"key":"10.1016\/j.jsat.2021.108276_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2020.102901","article-title":"No \u201cback to normal\u201d after COVID-19 for our failed drug policies","author":"del Pozo","year":"2020","journal-title":"The International Journal on Drug Policy."},{"key":"10.1016\/j.jsat.2021.108276_bb0015","doi-asserted-by":"crossref","DOI":"10.1097\/ADM.0000000000000703","article-title":"COVID-19 as a frying pan: The promise and perils of pandemic-driven reform","author":"Del Pozo","year":"2020","journal-title":"Journal of Addiction Medicine."},{"key":"10.1016\/j.jsat.2021.108276_bb0020","series-title":"Federal REGULATION OF METHADONE TREATMENT","article-title":"Methadone diversion control","author":"Institute of Medicine (US) Committee on Federal Regulation of Methadone Treatment","year":"1995"},{"issue":"4","key":"10.1016\/j.jsat.2021.108276_bb0025","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.1097\/ADM.0000000000000684","article-title":"Opioid use disorder and COVID-19: Crashing of the crises","volume":"14","author":"Khatri","year":"2020","journal-title":"Journal of Addiction Medicine"},{"key":"10.1016\/j.jsat.2021.108276_bb0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drugalcdep.2015.12.021","article-title":"Opioid substitution therapy: Lowering the treatment thresholds","volume":"161","author":"Kourounis","year":"2016","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.jsat.2021.108276_bb0035","doi-asserted-by":"crossref","first-page":"108074","DOI":"10.1016\/j.jsat.2020.108074","article-title":"Lessons from COVID 19: Are we finally ready to make opioid treatment accessible?","volume":"117","author":"Krawczyk","year":"2020","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.jsat.2021.108276_bb0040","doi-asserted-by":"crossref","DOI":"10.1097\/ADM.0000000000000678","article-title":"Optimizing medication treatment of opioid use disorder during COVID-19 (SARS-CoV-2)","author":"Leppla","year":"2020","journal-title":"Journal of Addiction Medicine."},{"key":"10.1016\/j.jsat.2021.108276_bb0045","article-title":"Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence","volume":"3","author":"Mattick","year":"2009","journal-title":"The Cochrane Database of Systematic Reviews"},{"key":"10.1016\/j.jsat.2021.108276_bb0050","first-page":"1","article-title":"Rapid implementation of service delivery changes to mitigate COVID-19 and maintain access to methadone among persons with and at high-risk for HIV in an opioid treatment program","author":"Peavy","year":"2020","journal-title":"AIDS and Behavior"},{"key":"10.1016\/j.jsat.2021.108276_bb0055","author":"Substance Abuse and Mental Health Services Administration"},{"issue":"3","key":"10.1016\/j.jsat.2021.108276_bb0060","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1097\/ADM.0b013e3182584772","article-title":"Methadone dose, take home status, and hospital admission among methadone maintenance patients","volume":"6","author":"Walley","year":"2012","journal-title":"Journal of Addiction Medicine"},{"issue":"4","key":"10.1016\/j.jsat.2021.108276_bb0065","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1097\/ADM.0b013e318155980e","article-title":"Premature deaths after discharge from methadone maintenance: A replication","volume":"1","author":"Woody","year":"2007","journal-title":"Journal of Addiction Medicine"}],"container-title":["Journal of Substance Abuse Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740547221000027?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740547221000027?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T19:52:55Z","timestamp":1760039575000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0740547221000027"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":13,"alternative-id":["S0740547221000027"],"URL":"https:\/\/doi.org\/10.1016\/j.jsat.2021.108276","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.08.31.20185249","asserted-by":"object"}]},"ISSN":["0740-5472"],"issn-type":[{"value":"0740-5472","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Take-home dosing experiences among persons receiving methadone maintenance treatment during COVID-19","name":"articletitle","label":"Article Title"},{"value":"Journal of Substance Abuse Treatment","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsat.2021.108276","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"108276"}}